Lenvatinib plus pembrolizumab combination therapy in patients with radioiodine-refractory (RAIR), progressive differentiated thyroid cancer (DTC): Results of a multicenter phase II international thyroid oncology group trial.

被引：3

作者：

Haugen, Bryan

French, Jena

Worden, Francis P.

Konda, Bhavana

Sherman, Eric Jeffrey

Dadu, Ramona

Gianoukakis, Andrew G.

Wolfe, Eric G.

Foster, Nathan R.

Bowles, Daniel W.

Wirth, Lori J.

机构：

[1] Univ Colorado, Aurora, CO USA

[2] Univ Colorado Denver, Aurora, CO USA

[3] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 USA

[4] Ohio State Univ, Dept Internal Med, Comprehens Canc Ctr, Div Med Oncol, Columbus, OH 43210 USA

[5] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[7] UCLA, David Geffen Sch Med, Torrance, CA USA

[8] Mayo Clin, Rochester, MN USA

[9] Mayo Clin, Alliance Stat & Data Ctr, Rochester, MN USA

[10] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[11] Harvard Univ, Boston, MA 02115 USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

6512

引用

页数：2